Clinical Trial

Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma

Study acronym: NeoLeap-HCC
Unknown Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab as a neoadjuvant therapy in subjects with resectable hepatocellular carcinoma (HCC).
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05389527
Lead Sponsor Shanghai Zhongshan Hospital
Collaborators: Merck Sharp & Dohme LLC
Conditions Carcinoma, Hepatocellular
Enrollment 43 participants
Start Date 2022-09-30
Primary Completion 2023-12-15 (estimated)
Study Completion 2025-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-11